指南与共识流行病学与生物统计临床试验与 GCP

呼吁在阿片类药物成瘾临床试验中统一疗效定义:系统综述与患者定性研究联合结果

A call for consensus in defining efficacy in clinical trials for opioid addiction: combined results from a systematic review and qualitative study in patients receiving pharmacological assisted therapy for opioid use disorder.
指南 / 共识 · Trials · 2020-01-06

该系统综述检索9个数据库至2015年8月1日,纳入60项阿片成瘾临床试验,提取并归类结局指标;同时对18名接受美沙酮治疗的成人进行半结构化访谈。结果显示结局指标高度异质:共21个具体结局、53个亚域和118种测量,持续阿片使用与治疗保留最常见(46%,n=28);患者认为戒断是主要目标,但试验中报告不足。作者呼吁统一疗效定义。

要点

  • 阿片成瘾临床试验结局指标高度异质,共21个具体结局、118种测量。
  • 持续阿片使用与治疗保留是最常报告的指标(46%,n=28)。
  • 患者重视戒断,但该目标在临床试验中报告不足。

核心结论

  • 阿片替代与拮抗治疗试验的疗效评价指标不一致,缺乏金标准。
  • 个体与群体决策所依据的疗效标准与患者认为重要的目标存在直接冲突。

研究设计与样本

  • 系统综述检索9个常用数据库(如EMBASE、MEDLINE),从建库至2015年8月1日。
  • 纳入60项阿片成瘾临床试验,提取结局并按既定域分类。
  • 对18名接受美沙酮治疗的成人进行半结构化访谈以评估患者报告的治疗目标。

主要发现

  • 结局归类为8个广泛域后,识别出21个具体结局、53个亚域和118种测量。
  • 持续阿片使用和治疗保留是最常报告的措施(46%,n=28)。
  • 多数患者同意戒断阿片是治疗的主要目标,同时强调临床试验中报告不足的目标。

临床怎么用

  • 解读OSAT试验结果时需注意结局指标异质性,避免直接比较不同试验的疗效。
  • 设计或评价阿片成瘾试验时应考虑纳入患者认为重要的治疗目标。

局限性

  • 系统综述检索截止2015年8月1日,未覆盖此后发表的试验。
  • 患者定性研究仅纳入18名接受美沙酮治疗的成人,样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Given the complex nature of opioid addiction treatment and the rising number of available opioid substitution and antagonist therapies (OSAT), there is no 'gold standard' measure of treatment effectiveness, and each successive trial measures a different set of outcomes which reflect success in arbitrary or opportune terms. We sought to describe the variation in current outcomes employed across clinical trials for opioid addiction, as well as determine whether a discrepancy exists between the treatment targets that patients consider important and how treatment effectiveness is measured in the literature. METHODS: We searched nine commonly used databases (e.g., EMBASE, MEDLINE) from inception to August 1, 2015. Outcomes used across trials were extracted and categorized according to previously established domains. To evaluate patient-reported goals of treatment, semi-structured interviews were conducted with 18 adults undergoing methadone treatment. RESULTS: We identified 60 trials eligible for inclusion. Once outcomes were categorized into eight broad domains (e.g., abstinence/substance abuse), we identified 21 specific outcomes with furthermore 53 subdomains and 118 measurements. Continued opioid use and treatment retention were the most commonly reported measures (46%, n = 28). The majority of patients agreed that abstinence from opioids was a primary goal in their treatment, although they also stressed goals under-reported in clinical trials. CONCLUSIONS: There is inconsistency in the measures used to evaluate the effectiveness of OSATs. Individual and population level decision making is being guided by a standard of effect considered useful to researchers yet in direct conflict with what patients deem important. TRIAL REGISTRATION: PROSPERO, CRD42013006507.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Dennis BB, Sanger N, Bawor M, et al. A call for consensus in defining efficacy in clinical trials for opioid addiction: combined results from a systematic review and qualitative study in patients receiving pharmacological assisted therapy for opioid use disorder. Trials. 2020. PMID: 31907000. doi:10.1186/s13063-019-3995-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。